Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

Key Points

• Dimensional Fund Advisors increased its Perspective Therapeutics stake by 391.6%, purchasing 358,540 additional shares to own 450,097 shares valued at approximately $1.88 million. Institutional investors collectively hold 54.66% of CATX.
• Perspective Therapeutics reported a quarterly loss of $0.22 per share, beating estimates of a $0.25 loss, while revenue of $80,000 was slightly below expectations. Analysts forecast a full-year loss of $1.07 per share.
• CATX recently traded at $3.10, down 4.9%, but analysts maintain a consensus “Buy” rating with an average price target of $12.38; the company is advancing precision-targeted alpha therapies in Phase 1/2a trials for cancer treatment.

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) by 391.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 450,097 shares of the company's stock after buying an additional 358,540 shares during the quarter. Dimensional Fund Advisors LP owned about 0.39% of Perspective Therapeutics worth $1,877,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock worth $4,758,000 after purchasing an additional 188,887 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company's stock valued at $2,573,000 after purchasing an additional 405,612 shares during the last quarter. Walleye Capital LLC raised its stake in Perspective Therapeutics by 375.8% during the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company's stock valued at $645,000 after buying an additional 148,013 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Perspective Therapeutics by 44.4% in the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company's stock valued at $671,000 after acquiring an additional 60,019 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company's stock worth $1,127,000 after purchasing an additional 25,697 shares during the period. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Stock Down 4.9%

CATX opened at $3.10 on Friday. The stock's 50 day moving average price is $3.08 and its 200-day moving average price is $3.94. Perspective Therapeutics, Inc. has a one year low of $1.96 and a one year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%.The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. Equities analysts forecast that Perspective Therapeutics, Inc. will post -1.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. BTIG Research reaffirmed a "buy" rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Finally, Piper Sandler dropped their price target on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $12.38.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source